Abstract: The invention relates to vapor absorption refrigeration. The invention provides methods for carrying out vapor absorption refrigeration, and a vapor absorption refrigeration installation. The invention provides also a method for operating an absorption stage of a vapor absorption refrigeration system and an absorption stage installation for a vapor absorption refrigeration installation.

Abstract: Vapour absorption refrigeration is carried out by condensing, in a condensing stage (98), a refrigerant in vapour form to obtain condensed refrigerant, being passed into an expansion/evaporation stage (16) in which it is subjected to heat transfer with a higher temperature medium (29) such that at least some of the refrigerant evaporates. Vapourised refrigerant passes from the evaporation stage into an absorption stage (30) in which some of it is absorbed, at a first pressure, into an absorbent, thereby to obtain partially refrigerant-enriched absorbent. This absorbent is contacted, in a compression absorption stage (58) at a second pressure greater than the first pressure, with vapourised refrigerant, rendering refrigerant-enriched absorbent which is passed from the compression absorption stage into a refrigerant regeneration stage (62), in which refrigerant in vapour form is recovered, rendering refrigerant-depleted absorbent.

Abstract: The present invention relates to pharmaceutical compositions containing the antifolate aminopterin, processes for making the compositions, and methods of using them to treat disorders in adult and pediatric patients. Pharmaceutical compositions substantially free of impurities are provided comprising a therapeutically effective amount of aminopterin, or a pharmaceutically acceptable salt thereof. Relative to the teachings of the prior art, the disclosed methods and compositions provide unexpected improvements that include a greater interpatient oral bioavailability in pediatric patients, a smaller interpatient coefficient of variation of oral bioavailability, a smaller mean intrapatient coefficient of variation of oral bioavailability, a greater therapeutic index, a smaller coefficient of variation of toxicity, efficacy in combination therapy, and efficacy of certain polyglutamated metabolites.